About This Information
This section provides supplementary clinical context for the Dupixent (dupilumab) Dosing Calculator. Dupilumab is a monoclonal antibody used to treat various inflammatory conditions. The dosing regimens are specific to each FDA-approved indication and may depend on patient age and body weight. Always use this information as a supplement to, not a replacement for, clinical judgment and the full Prescribing Information.
Understanding the Outputs
The calculator provides the following key dosing parameters based on the inputs provided:
- Loading Dose: The initial higher dose required for certain indications to quickly achieve therapeutic levels. For some regimens, a loading dose is not applicable.
- Maintenance Dose: The regular, ongoing dose administered after the loading dose. This includes the dosage strength and frequency (e.g., every 2 weeks, every 4 weeks, or weekly).
- Device Options: The available pre-filled pen or syringe strengths (e.g., 100 mg, 200 mg, 300 mg) appropriate for the calculated dose.
How to Use the Calculator
To determine the appropriate dosing regimen, follow these steps:
- Select Indication: Choose the relevant FDA-approved condition from the dropdown list.
- Select Patient Age: Choose the appropriate age group for the selected indication. The available options will update automatically.
- Enter Patient Weight: If required for the selected age and indication (typically for pediatric patients), enter the body weight and select the unit (kg or lbs).
- Specify Asthma Type: For patients 12 years and older with asthma, specify if the standard dosing applies or if the patient is oral corticosteroid (OAD)-dependent or has comorbid moderate-to-severe atopic dermatitis.
- Calculate: Click the "Calculate" button to view the recommended dosing schedule.
Dosing Overview
Dupixent is administered as a subcutaneous injection. Dosing varies significantly by indication, age, and sometimes weight.
- Adult Dosing (AD, PN): Typically involves a 600 mg loading dose followed by 300 mg every two weeks.
- Pediatric Dosing (AD, Asthma, EoE): Often weight-based, with different loading and maintenance schedules for various weight brackets.
- Asthma Dosing: Adults and adolescents may receive a higher dose (600 mg loading, 300 mg every two weeks) if they are OAD-dependent or have comorbid AD.
- EoE Dosing: Uniquely features a weekly administration schedule for certain patient populations (300 mg weekly for patients ≥12 years and ≥40 kg).
- CRSwNP Dosing: A consistent 300 mg every two weeks without a loading dose.
Switching Therapies
There are no specific guidelines in the prescribing information for switching from other biologics to Dupixent. The decision to switch, including any necessary washout period, should be made by a qualified healthcare provider based on the patient's clinical history and the specific agents involved.
Missed Dose Instructions
According to the prescribing information, if a dose is missed, the patient should administer the injection as soon as possible. After that, they should resume the regular dosing schedule from the date of the most recent injection. For weekly dosing regimens, if a dose is missed, administer the dose as soon as possible and start a new weekly schedule from the time of the injection.
Safety Alerts
This tool does not provide safety information. Dupixent is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients. Refer to the full Prescribing Information for a complete list of warnings, precautions, adverse reactions, and contraindications before initiating therapy.
Frequently Asked Questions
The calculator covers FDA-approved indications including Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), Eosinophilic Esophagitis (EoE), and Prurigo Nodularis (PN).
Dosing for several pediatric indications (AD, Asthma, EoE) is weight-dependent to ensure proper exposure and efficacy. For most adult indications, a fixed dose is used regardless of weight.
For patients aged 12 and older with asthma, a higher dose regimen is recommended if they are dependent on oral corticosteroids (OAD) or have a comorbid diagnosis of moderate-to-severe atopic dermatitis.
For children aged 6-11 years with asthma weighing 15 to <30 kg, the Prescribing Information allows for two equivalent maintenance schedules: 100 mg every 2 weeks or 300 mg every 4 weeks, providing flexibility for the patient and provider.
This indicates that the FDA-approved regimen for that specific indication and patient group does not require an initial, higher loading dose. Therapy begins directly with the maintenance dose.
The regimen for EoE in patients 12 years and older (≥40 kg) is unique, requiring 300 mg administered every week, which is more frequent than other indications.
Yes, the dosing regimen for adults with Prurigo Nodularis is the same as for adults with Atopic Dermatitis: an initial 600 mg loading dose, followed by 300 mg every two weeks.
No. The calculator is strictly based on the FDA-approved Prescribing Information for the specified indications and does not provide recommendations for any off-label use.
References
- DUPIXENT® (dupilumab) Prescribing Information. Regeneron Pharmaceuticals, Inc. and sanofi-aventis U.S. LLC. Last revised: October 2023.
- Dupixent HCP Official Website. Sanofi and Regeneron Pharmaceuticals, Inc. Accessed May 2024.
- Drugs@FDA: DUPIXENT (dupilumab) injection, for subcutaneous use. U.S. Food and Drug Administration.
- Dupixent | European Medicines Agency. European Medicines Agency.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com